Phibro Animal Health Corporation (PAHC) EPS Estimated At $0.44

August 13, 2018 - By Russell Jones

Investors sentiment decreased to 1.32 in Q1 2018. Its down 0.09, from 1.41 in 2017Q4. It worsened, as 9 investors sold Phibro Animal Health Corporation shares while 53 reduced holdings. 26 funds opened positions while 56 raised stakes. 18.04 million shares or 5.73% less from 19.14 million shares in 2017Q4 were reported.
Principal Financial Gru Inc reported 160,503 shares. 3,949 were reported by Mckinley Cap Management Limited Liability Company Delaware. 642,901 are held by Invesco Limited. Manufacturers Life Insur The has 15,591 shares for 0% of their portfolio. Moreover, Advisory Ser has 0% invested in Phibro Animal Health Corporation (NASDAQ:PAHC). D E Shaw And Com has invested 0% of its portfolio in Phibro Animal Health Corporation (NASDAQ:PAHC). Morgan Stanley holds 0% or 111,661 shares in its portfolio. First Tru Advsr L P holds 0% or 18,817 shares. New York State Teachers Retirement Sys holds 0% or 13,065 shares in its portfolio. Spark Invest Management Ltd holds 0.03% or 13,600 shares. Ameriprise Financial stated it has 388,969 shares or 0.01% of all its holdings. Metropolitan Life Communications Ny has invested 0% in Phibro Animal Health Corporation (NASDAQ:PAHC). Royal Bank Of Canada has invested 0% in Phibro Animal Health Corporation (NASDAQ:PAHC). 53,450 are held by Los Angeles Cap Management Equity Research. First Quadrant Lp Ca holds 0.01% in Phibro Animal Health Corporation (NASDAQ:PAHC) or 18,097 shares.

Since February 9, 2018, it had 0 insider buys, and 29 insider sales for $28.07 million activity. $837,134 worth of stock was sold by BENDHEIM JACK on Tuesday, July 17. 23,163 shares were sold by Bendheim Daniel M, worth $926,717 on Thursday, March 8. Another trade for 10,000 shares valued at $356,200 was made by Warras Dean J on Friday, February 9. On Wednesday, February 14 Miller Larry Lee sold $630,886 worth of Phibro Animal Health Corporation (NASDAQ:PAHC) or 17,928 shares.

Analysts expect Phibro Animal Health Corporation (NASDAQ:PAHC) to report $0.44 EPS on August, 27 after the close.They anticipate $0.05 EPS change or 12.82 % from last quarter’s $0.39 EPS. PAHC’s profit would be $17.74M giving it 27.87 P/E if the $0.44 EPS is correct. After having $0.46 EPS previously, Phibro Animal Health Corporation’s analysts see -4.35 % EPS growth. The stock decreased 0.20% or $0.1 during the last trading session, reaching $49.05. About 53,006 shares traded. Phibro Animal Health Corporation (NASDAQ:PAHC) has risen 28.06% since August 13, 2017 and is uptrending. It has outperformed by 15.49% the S&P500.

Phibro Animal Health Corporation (NASDAQ:PAHC) Ratings Coverage

Among 2 analysts covering Phibro Animal Health (NASDAQ:PAHC), 0 have Buy rating, 1 Sell and 1 Hold. Therefore 0 are positive. Phibro Animal Health had 2 analyst reports since May 9, 2018 according to SRatingsIntel. The firm earned “Neutral” rating on Wednesday, May 9 by Credit Suisse. The company was maintained on Thursday, July 5 by Barclays Capital.

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition firm primarily in the United States. The company has market cap of $1.98 billion. It operates through three divisions: Animal Health, Mineral Nutrition, and Performance Products. It has a 34.06 P/E ratio. The firm develops, makes, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

More news for Phibro Animal Health Corporation (NASDAQ:PAHC) were recently published by: Globenewswire.com, which released: “Phibro Animal Health Corporation Declares Quarterly Dividend” on July 30, 2018. Nasdaq.com‘s article titled: “Analysis: Positioning to Benefit within BioTelemetry, Genworth Financial, Power Integrations, Phibro Animal Health …” and published on August 06, 2018 is yet another important article.

Phibro Animal Health Corporation (NASDAQ:PAHC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.